A B S T R A C T The purpose of the present study was to investigate the regulation of insulin biosynthesis during the perinatal period. The incorporation of [3H]leucine into total immunoreactive insulin (IRI) and into IRI fractions was measured by a specific immunoprecipitation procedure after incubation, extraction, and gel filtration in isolated 3-day-old rat pancreases without prior isolation of islets. IRI fractions were identified by their elution profile, their immunological properties, and their ability to compete with the binding of "I-insulin in rat liver plasma membranes. No specific incorporation of [3H]leucine was found in the IRI eluted in the void volume, making it unlikely that this fraction behaves as a precursor of (pro)insulin in this system. In all conditions tested, the incorporation of [8H]leucine was linearly correlated with time. Optimal concentration of glucose (11 mM cose and was not modified by any further increase in glucose concentrations up to 27.5 mM. Theophylline or dbcAMP at 10 mM concentration did not reverse the somatostatin inhibitory effect on either insulin biosynthesis or release. Somatostatin also inhibited both processes in isolated islets from the 3-day-old rat pancreas. High Ca"+ concentration in the incubation medium reversed the inhibitory effect of somatostatin on glucoseinduced insulin biosynthesis as well as release. In both systems the inhibitory effect of somatostatin on insulin biosynthesis and release correlated well. Glipizide (10-100 ,M) and tolbutamide (400 ELM) inhibited the stimulatory effect of glucose, dbcAMP, and theophylline on [8H]leucine incorporation into IRI. The concentrations of glipizide that were effective in inhibiting [3H]leucine incorporation into IRI were smaller than those required to inhibit the phosphodiesterase activity in isolated islets of 3-day-old rat pancreas.
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In all conditions tested, the incorporation of [8H]leucine was linearly correlated with time. Optimal concentration of glucose (11 mM) activated six-to sevenfold the [8H]leucine incorporation into IRI. Theophylline or N602-dibutyryl-(db) cAMP at 1.6 mM glucose significantly increased the [8H]leucine incorporation. Glucose at 16.7 mM further enhanced the effect of both drugs. Contrarily, somatostatin (1-10 ig/ml) inhibits the rate of [8H]leucine incorporation into IRI in the presence of 11 mM glucose; this effect was observed at 5.5 mM gluDr. S. Duran Garcia's permanent address is the Department of Internal Medicine, Faculty of Medicine, Valladolid, Spain. He is supported by Institut National de la Sante et de la Recherche Medicale service fellowship award and by the Ministerio de Education y Ciencia espafiol.
cose and was not modified by any further increase in glucose concentrations up to 27.5 mM. Theophylline or dbcAMP at 10 mM concentration did not reverse the somatostatin inhibitory effect on either insulin biosynthesis or release. Somatostatin also inhibited both processes in isolated islets from the 3-day-old rat pancreas. High Ca"+ concentration in the incubation medium reversed the inhibitory effect of somatostatin on glucoseinduced insulin biosynthesis as well as release. In both systems the inhibitory effect of somatostatin on insulin biosynthesis and release correlated well. Glipizide (10-100 ,M) and tolbutamide (400 ELM) inhibited the stimulatory effect of glucose, dbcAMP, and theophylline on [8H]leucine incorporation into IRI. The concentrations of glipizide that were effective in inhibiting [3H]leucine incorporation into IRI were smaller than those required to inhibit the phosphodiesterase activity in isolated islets of 3-day-old rat pancreas.
These data suggest the following conclusions: (a) the role of the cAMP-phosphodiesterase system on insulin biosynthesis is likely to be greater in newborns than in adults; (b) the greater effectiveness of glucose and the cAMP system on insulin biosynthesis than on insulin release might possibly be related to the rapid accumulation of pancreatic IRI which is observed in the perinatal period; (c) somatostatin, by direct interaction with the endocrine tissue, can inhibit glucose and cAMPinduced insulin biosynthesis as well as release; calcium reverses this inhibition; (d) sulfonylureas inhibit insulin biosynthesis in newborn rat pancreas an effect which has
INTRODUCTION
The capacity of the pancreatic beta cell to synthesize proinsulin and to convert it into insulin early in fetal life has been pointed out (1) . During the first days of life, glucose stimulates the ['H] leucine incorporation into insulin through proinsulin biosynthesis in isolated islets of rat pancreas (2) (3) (4) . Several agents which naturally occur in pancreas such as cAMP (5) (6) (7) and somatostatin (8) have ben postulated to play an important role in the regulation of insulin secretion in neonates (9) and in adults (5) (6) (7) (10) (11) (12) (13) (14) (15) (16) (17) (18) . However, there is currently no information available regarding the effect of somatostatin on insulin biosynthesis; moreover, the precise relationship between glucose, cAMP, and somatostatin on the beta cell function remains to be elucidated. On the other hand, drugs such as sulfonylureas (the use of which in diabetes is currently under question [19] ) have been postulated to act on insulin release through the cAMP system (20) (21) (22) . The effect of these drugs on insulin production is a matter of controversy because they have been reported to stimulate (23) or to inhibit (24) (25) (26) (27) proinsulin biosynthesis in isolated islets of adult rodents.
The chief aims of the present work are: (a) to elucidate the interactions of glucose, cAMP, and somatostatin in the regulation of insulin biosynthesis and (b) to test the effect of sulfonylureas on this regulation. These studies were carried out in isolated newborn rat pancreas because it is of great physiological interest to investigate insulin biosynthesis in a period when the development and the function of the endocrine pancreas are considerable and to correlate the results obtained to the insulin release which has previously been reported using the same system (9) . METHODS Materials. The rat and human insulins, 20 (28) ; monoiodinated insulin, 380 uCi/jsg (29) ; and monoiodinated-proinsulin, 250 /Ci/,g (30) were labeled by the chloramine-T method (31) . L-[4,5-'H]leucine (40 Analytical grade anion-exchange resin (AGI-X2) was from Bio-Rad, (Paris). Sephadex G-50 fine, dextran 250, and Ficoll 400 were from Pharmacia, (Le Chesnay, France). Other chemicals were of reagent grade.
Pancreas. The splenic lobes of the pancreas were removed from 3-day-old Wistar rats (9) . The rats were suckled until time of death. The explants (8-10 per flask) were collected at 40C in 40-50 ml of Krebs-Ringer bicarbonate buffer (KRB) containing 106 mM NaCI, 1 mM MgCl,* 1 mM CaCI2, 4 mM KCI, 40 mM NaHCOs, 0.5% (wt/vol) of dialyzed BSA, pH 7.5. They were gassed (95% 02, 5% C02) and preincubated in the same buffer for 30 min at 37'C. Incubation was done with shaking at 80 cpm in 0.8-1.0 ml of fresh medium containing the substances to be tested, 17 natural amino acids (Ala, Arg, Asp, Cys, Glu, Gly, His, Pro, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr, Val) at 0.1 mM each, and ['H]leucine at 500 #Ci/ml instead of leucine. These additives replaced an equimolar quantity of NaCl to maintain the isoosmolality.
Immunoreactive insulin (IRI) was extracted from the whole pancreas according to Kenny (32) with the following modifications: 80-100 mg of pancreas was homogenized in 8-10 ml of acid-alcohol solution (ethanol 75%o vol/vol, 12 N HC1 1.5%o vol/vol) by a 2-min sonication at 50 W in a Branson sonifier (Heat Systems-Ultrasonics, Inc., Plainview, N. Y.). The homogenate was adjusted to pH 4 with 0.5-1.0 ml of sodium citrate and centrifuged at 1,500 g for 5 min. The supernate was supplemented with 100 ,ul/ml insulin-free human plasma, and dialyzed for 2 h in a 10-ml hollow fiber dialyzer (Bio-Fiber 50 Minibaker) against 10 mM Na2HPO4, 150 mM NaCI, and 0.3% BSA.' After centrifugation and concentration of the supernate to 3-5 ml by rotary vacuum evaporation, ice-cold TCA was added to obtain a 10%o final concentration. After centrifugation, the precipitate was washed once with 5%o TCA and dried with a mixture of ether-acetone (1/1, vol/vol) then with ether. The IRI recovered in the TCA precipitate was 85.7±2.6%o of the acid-alcohol IRI (10 extractions). The dried TCA precipitate was then dissolved in I ml of 1 M acetic acid and applied to a I X 130-cm column of Sephadex G-50 fine. The column was equilibrated and eluted at 4'C with 1 M acetic acid at a flow rate of 10 ml/h. 1-ml fractions were collected in tubes containing 1 mg BSA in 100 Id H2O, to minimize the adsorption of IRI to the plastic wall. The fractions were pooled according to the distribution of IRI and to the calibration as indicated in Fig. 1 insulin or proinsulin-like material (PLM), and pool III included the IRI eluted with the "TI-rat insulin.
Islets. Islets of 3-day-old rat pancreases were isolated as described elsewhere for adult pancreas (33) . 50 islets per tube were directly incubated for various times in 500
Al of the KRB medium described above containing 50 (34) . It was verified with 'I-hormone as tracer that 10 mU IRI/ml was completely bound by 2,l/ml of the guinea pig antiinsulin serum (AIS). Virtually all (98±0.3%, n = 10) of the insulin-anti-insulin complex was precipitated by the (35) before addition of GAGP serum (Table I ). In the conditions indicated in Table I (42) . 232 S. Duran Garcia, C. Jarrousse, and G. Rosselin RESULTS Effect of glucose and different drugs on the distribution of IRI after gel chromatography fractionation. The IRI content of newborn rat pancreas after 4 h incubation with [3H]leucine in different experimental conditions was measured and characterized in the pools that were collected after gel filtration on Sephadex G-50 fine (Fig. 1) . The IRI that is eluted in the void volume (pool I) follows the same dilution curve as rat insulin used as standard ( Fig. 2 ) and thus can be measured in terms of rat insulin. The elution pattern of this pool remains unchanged when it is rechromatographed under the same conditions. These properties are similar to those described for "big big" insulin in human plasma (43) . In contrast to the observations made in a human insulinoma (44) , no specific incorporation of ['H]leucine is found in this fraction, making it unlikely that this "big big" insulin behaves as a precursor of (pro)insulin in the newborn rat pancreas. A quantity of this IRI equivalent to 50 ng/ml insulin did not produce a significant competition in the radioreceptor assay system used (40): B/Bo X 100 = 97.2+2.1% (n = 3) as compared to 25 .2±2.3% (n = 3) observed with the same quantity of rat insulin. PLM has properties similar to those of rat proinsulin used as standard when identified by the elution profile (Fig. 1) , the immunological properties (see Methods) and the ability to compete with the binding of 'I-insulin to liver plasma membranes ( Fig. 3 ): in this radioreceptor assay the y intercept obtained with PLM differs significantly (P < 0.001) from that obtained with rat insulin used as standard, whereas slopes mu/ml 1251.pRo 131 FNS 100 so-36 46 76EkJtion aose I 1 1 IRI POOLS FIGURE 1 Elution profile of pancreatic IRI after gel filtration on Sephadex G-50 fine. 3-day-old rat pancreases were incubated for 4 h in a medium containing 16.7 mM glucose. After extraction, the TCA precipitate was fractionated in a 1 X 130-cm column and was eluted with 1 M acetic acid. Dotted lines show the optical density of proteins eluted in the void volume as measured at 280 nm in 1 to 10 diluted samples. Insulin content in each fraction was radioimmunoassayed using a pure rat insulin as standard. Details of the incubation, extraction, and gel chromatographic procedure are given in Methods. (Fig. 4, right) . Glucose is maximally effective from 11 to 27.5 mM with a six-to sevenfold incorporation, as compared to the effect of 1.6 mM glucose. About 5 mM glucose is required to produce 50% stimulation of [5H]leucine incorporation. The glucose dose effect is not dependent on the duration of the experiments within a 4-h period, since the incorporation of [3H] leucine into IRI is linearly correlated with time (Fig. 4, left) : at 11 mM glucose, the slope of the regression line is about 3.8 fmol [8H]IRI/explant per min (r: 0.99, P < 0.001). This suggests that the transfer of the radioactivity from the precursor pool of amino acids into the IRI behaves as a zero-order process, in agreement with the model of the precursor-product relationship described by Steiner et al. (45) . After 240 min, glucose at 16.7 mM enhances slightly (but not significantly) the percentage of [5H]leucine incorporated into the insulin pool to 54.3±3.9 as compared to 37.9±8.7 at 1.6 mM glucose (Table IV) .
Theophylline at 10 mM significantly increases the
[3H] IRI at both high and low glucose concentrations (Table IV) . Kinetic studies (Fig. 5, left (Table IV) . dbcAMP causes a 6-24-fold increase in [5H]leucine incorporation into IRI (Table IV) . At 16.7 and at 1.6 mM glucose, 50% stimulation is observed at about 0.7 and 1.5 mM dbcAMP, and nearly maximal stimulation is achieved with 5 mM dbcAMP (Fig. 6) (Table IV) . Effect of somatostatin on the specific incorporation of [3H]leucine into IRI. When isolated newborn rat pancreas was incubated as previously described (9) for 90 min at 11 mM glucose, the addition of somatostatin (0.5-1.0 Mg/ml) inhibited the glucose-induced insulin release (Table V) Each explant was incubated as previously described (9) for 90 min at 11 mM glucose. Values in parenthesis indicate the number of experiments. Statistical significance of the somatostatin effect for each experiment is given by comparison to the respective controls and indicated by *P < 0.001, tP < 0.01, and §P < 0.05. on insulin biosynthesis (Fig. 7, center) . Time-course studies in the presence of somatostatin (Fig. 7, right) show that the decrease in [5H]leucine incorporation is observed for the first experimental point measured (30 min); the incorporation of [5H]leucine into IRI is linearly correlated with time, with a rate of about 1.9 (r: 0.98, P < 0.01) fmol/explant per min. Somatostatin also inhibits the stimulatory effect of theophylline or dbcAMP on the glucose-induced [5H]leucine incorporation (Fig. 8) . The effect of 10 mM theophylline or of 10 mM dbcAMP on the [5H]leucine incorporation induced by 11 mM glucose after 150 min of incubation is decreased with a concentration of somatostatin of 1 Ag/ml (P < 0.05 and P < 0.01, respectively).
The effect of somatostatin was also studied in isolated islets from newborn rat pancreas, since it had been reported that the effect of somatostatin on insulin release was no longer observed in isolated islets (14, 46) . So- (Fig. 5, right) . The (Table VIII) are different from those with theophylline alone, at the same glucose concentration, the significance is given by * P < 0.05, TP < 0.01, § P < 0.001.
Each experiment was done with 8-10 explants.
examined. The rate of hydrolysis of cAMP due to islet phosphodiesterase at a linear dilution was studied with various concentrations of this substrate (Fig. 11, left) .
Estimates of the apparent Km derived from the Lineweaver-Burk plot give a value of 3.2 AM cAMP. Glipizide (500 AM) decreases the Vrax without altering the apparent Km; thus the inhibitory effect of glipizide is noncompetitive. The apparent K, for glipizide was studied with a low concentration of cAMP (25 nM). i.e., a concentration that is in the range of the cAMP concentration in the islets (Fig. 11, right) ; under these conditions, the apparent Ki is about 350 AM glipizide.
DISCUSSION
As a result of previous studies (23, 27, 34, 36, (49) (50) (51) (52) , it is known that glucose, theophylline, and dbcAMP stimulate insulin biosynthesis in isolated adult mammalian islets. In the present studies, we have been able to measure the specific incorporation of [3H] leucine into pancreatic IRI directly without prior isolation of islets and to indicate possible mechanism for the regulation of insulin biosynthesis in newborns. Our results demonstrate that glucose and cAMP are involved in insulin biosynthesis in newborn rats as in adults and, In each experiment 8-10 explants were incubated at 37°C as described in Methods.
Cycloheximide and actinomycin D was added at 0 time of incubation. Each measure is mean of triplicate determinations; individual values did not differ by more than 5%.
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S. Duran Garcia, C. Jarrousse, and G. Rosselin furthermore, that somatostatin, a substance that naturally occurs in the pancreas (8) , is able to oppose the effect of both these agents. The comparison of the effects of glucose or of the cAMP showed that in newborns, unlike in adults, theophylline and dbcAMP appeared to be more efficient than glucose in inducing insulin biosynthesis. Another approach is to compare our results to relevant data reported by separate investigators: maximal stimulation in newborns was here achieved by 11 mM glucose and represented a sixfold increase. Pipeleers et al. (50) estimated that 16.7 mM glucose is further effective and determines a 10-fold increase of insulin biosynthesis in isolated islets of adult rats. 10 mM theophylline induced a stimulation which represents a 4-fold increase in newborns whereas in adults, the effect of this agent does not exceed the control value by more than 2-fold without theophylline (23, 51) ; the increase by dbcAMP of [3H]leucine incorporation into IRI in newborn is considerable, 6-24-fold the corresponding control and has to be compared to the only 2-fold increase obtained in adults (23, 51, 52) . These results indicate how well developed in neonates is the ability of the endogenous cAMP system to act on insulin biosynthesis and the marked response of beta cell to dbcAMP. Furthermore, the greater effectiveness of theophylline may be related to the inhibition of the phosphodiesterase that was found more active in islets of neonates than in adults (53) .
From these studies it can be postulated that the cAMPphosphodiesterase system plays a more important role in neonatal islet function than in adults.
Under the conditions of this investigation, it was possible to obtain quantitative data on insulin biosynthesis in the same model as previously used for studying insulin release (9) such that quantitative responses to different agents could be obtained in neonates. This is of great physiological interest since in the 3-day-old rat pancreas regulation of insulin biosynthesis and release occurs in a period of islet and beta cell growth (54) and functional differentiation. Indeed, insulin content on the 3rd (55) day after birth rises to twice the insulin content of the 1st day of life (55) . In this respect two points are noteworthy. First, the lower limit of glucose required to induce insulin biosynthesis was below that required to elicit insulin release: 50% of the effect was observed with 4-5 and 7-8 mM glucose, respectively for biosynthesis and for release (9) . Second, theophylline and dbcAMP, which did not act on insulin release at low glucose concentration (9) (11, 12, 57) or increase the cAMP levels of islets in the presence (58) or in the absence (33) of phosphodiesterase inhibitors. The fact that, in our experiments, glucose plus theophylline stimulated insulin biosynthesis synergistically would favor these hypotheses. However, up to now, the stimulatory effect of glucose on cAMP in islets has been described for 16.7-27.5 mM glucose, i.e., a higher concentration that is sufficient to induce insulin biosynthesis. On the other hand, the percentage of newly synthesized insulin is significantly different for glucose (54%) and for dbcAMP (89%) or theophylline (87%). This per-centage was measured after a 4-h period because at that time the amount of radioactivity in proinsulin reaches a steady state between the formation of proinsulin and the conversion of proinsulin to insulin (see Table IV , [45] ). The finding that dbcAMP and theophylline increased the percentage of [3H]insulin suggests that these two drugs influence not only the proinsulin synthetic activity but also the process of conversion of proinsulin to insulin. However, although these agents did not modify the linearity of [8H] leucine incorporation in total IRI, a relative increase in the incorporation of this amino acid into insulin pool might result from a decline in the biosynthetic rate for proinsulin during the latter half of the incubation period. Furthermore, dbcAMP and theophylline could also act on [8H]leucine incorporation into total IRI (proinsulin + insulin) by modifyng the size of the amino acid precursor pool. Although our data did not allow us to localize precisely the mechanism(s) of glucose and cAMP action on insulin biosynthesis, the fact that actinomycin D inhibited glucose-induced insulin biosynthesis after a delay of at least 90 min is in agreement with the existence of glucose-dependent mechanisms at the transcriptional levels (36, 59 ) without excluding its effect at the translational levels (36, 60) . On the other hand, time-course experiments of substances stimulating (theophylline, dbc-AMP) or inhibiting (somatostatin, sulfonylureas) insulin biosynthesis demonstrated an early effect which suggests they are acting at the post-transcriptional levels.
Somatostatin is known as a potent inhibitor of glucagon release (61-62) and of both the acute and the chronic phase of insulin secretion (14) (15) (16) (17) (18) . Because of its preferential action on glucagon (61) (62) , it has been found to be efficient in lowering blood glucose in experimental diabetes (15) and its use in human diabetes has been proposed. The present study shows that somatostatin was also able to inhibit glucose-induced insulin biosynthesis and release in isolated newborn rat pancreas. The doses that were effective (1-10 ug/ml) were similar to those used in the perfused rat pancreas to inhibit insulin release (14) . Furthermore, unlike the contradictory results concerning the disappearance of the release-suppressing effect of somatostatin (14, 46, 48, 63) in isolated islets, the inhibition of insulin biosynthesis and the release-suppressing effect were still present in our isolated islets obtained after a brief exposure to low doses of collagenase. This observation suggests a direct effect of somatostatin on the beta cell. Previous studies on the rat pituitary have shown that somatostatin lowers cAMP levels (64) . Even if similar effects on the endocrine pancreas could explain the inhibitory effect of somatostatin on glucose and theophylline action, it did not account for the inhibitory effect of this peptide on the dbcAMP-induced insulin biosynthesis and release. The fact that high Ca++ concentration reversed the inhibitory effect of somatostatin on glucose-induced insulin biosynthesis as well as release, favors the hypothesis that the mechanism of somatostatin inhibition may be involved with Ca++ inactivation or translocation at some step of the biosynthetic and secretory processes. However it has been shown that modifications in the extracellular concentrations of calcium which cause considerable changes in insulin release (65) did not modify insulin biosynthesis (60, 66) . Whether the effect of somatostatin is coupled to intracellular modifications of Ca++ and/or cAMP remains to be determined. It is not possible on the basis of presently available data to conclude that somatostatin is a physiological regulator of insulin biosynthesis and release since it is likely that the concentrations of endogenous (pancreatic and/or plasmatic) somatostatin are much smaller than the doses used in the present experiments; however, such inhibitory effects on insulin biosynthesis have to be taken into consideration in the use of somatostatin in human diseases.
The inhibitory effect of glipizide and tolbutamide on the glucose-induced biosynthesis was in agreement with results obtained by others in isolated islets of adult rodents (24) (25) (26) (27) . This inhibitory effect was not reversed by an increase in the intracellular levels of cAMP obtained by theophylline or by dbcAMP. Moreover the stimulatory properties of sulfonylureas on insulin release (i.e. an inhibition of the phosphodiesterase activity which in turn should increase cAMP in isolated islets [20] [21] [22] ) do not fit in with their inhibiting action on insulin biosynthesis, since a stimulation of the cAMP system causes a large increase of insulin biosynthesis (see above). An explanation for this discrepancy was that the doses of sulfonylureas that are required to be effective in inhibiting the phosphodiesterase activity in isolated islets were higher than the doses that are sufficient to inhibit the [3H]leucine incorporation into IRI (Fig. 11) . Therefore the action of these drugs on insulin biosynthesis must take place via non-cAMP mechanism or at a level beyond the cAMP system. Further investigations might suggest an interrelation between the inhibitory effect of sulfonylureas on insulin biosynthesis and the possible depression in the activity of beta cells which follows a long-term treatment of normal rats by these drugs (26) . Indeed a previous report on human diabetics shows that the secondary failure after successful therapy with sulfonylureas is a relatively common occurrence (67) . Moreover, the fact that sulfonylureas passed readily through the placenta (68) and were excreted by the mammary gland (69) provides additional reasons for avoiding their use during pregnancy and lactation for they may adversely affect the 240 S. Duran Garcia, C. Jarrousse, and G. Rosselin islet function in inhibiting insulin biosynthesis during the perinatal period.
